If you are found to be eligible to take part in this study, you will receive daratumumab by vein on Days 1, 8, 15, and 22 of Cycles 1 and 2, on Days 1 and 15 of Cycles 3-6, and then on Day 1 of Cycles 7 and beyond for up to 1 year or unless the disease stops responding to treatment, whichever is earlier.